


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	CABAZITAXEL
PRONUNCIATION	ka baz" i tax' el
THERAPEUTIC CLAIM	Treatment of metastatic prostate cancer

CHEMICAL NAMES

1. Benzenepropanoic acid, β -[[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2*aR*,4*S*,4*aS*,6*R*,9*S*,11*S*,12*S*,12*aR*,12*bS*)-12*b*-(acetyloxy)-12-(benzoyloxy)-2*a*,3,4,4*a*,5,6,9,10,11,12,12*a*,12*b*-dodecahydro-11-hydroxy-4,6-dimethoxy-4*a*,8,13,13-tetramethyl-5-oxo-7,11-methano-1*H*-cyclodeca[3,4]benz[1,2-*b*]oxet-9-yl ester, (α *R*, β *S*)-
2. 1-hydroxy-7 β ,10 β -dimethoxy-9-oxo-5 β ,20-epoxytax-11-ene-2 α ,4,13 α -triyyl 4-acetate 2-benzoate 13-[(2*R*,3*S*)-{[(1,1-dimethylethoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate]

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₄₅ H ₅₇ NO ₁₄
MOLECULAR WEIGHT	835.9
TRADEMARK	None as yet
MANUFACTURER	Sanofi-Aventis
CODE DESIGNATION	XRP-6258
<u>CAS</u> REGISTRY NUMBER	183133-96-2